Statistics

Total Visits

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)38

Select a period of time:

Number of views in the range

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)20

Views

Views
March 202515
April 20252
May 20250
June 20251
July 20252
August 20250
September 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Austria2
Spain1
Turkey1
United States1
 

Top cities views

Views
Bursa1
Council Bluffs1
Vienna1